Kaya Holdings (KAYS) Capital Expenditures (2011 - 2024)

Kaya Holdings (KAYS) recorded quarterly Capital Expenditures of $8372.0 in Q4 2024, down 57.43% quarter-over-quarter from $19668.0 in Q1 2019.

Kaya Holdings (KAYS) Capital Expenditures (2011 - 2024) Analysis & Trends

Kaya Holdings' Capital Expenditures history runs 10 years deep, the most recent figure standing at $8372.0 for Q4 2024.

In Q4 2024, Capital Expenditures changed N/A year-over-year to $8372.0; the TTM figure through Dec 2024 stood at $8372.0 (changed N/A YoY), while the FY2024 annual figure was $27138.0, changed N/A from the prior year.
Capital Expenditures was $8372.0 for Q4 2024 at Kaya Holdings, down from $19668.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $8372.0 in Q4 2024 to a low of $8372.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Teva Pharmaceutical Industries	39.97 Bn	36.23 Bn	1.97 Bn	168.00 Mn
2	Zoetis	33.59 Bn	31.65 Bn	1.62 Bn	110.00 Mn
3	United Therapeutics	23.75 Bn	21.60 Bn	648.10 Mn	100.80 Mn
4	Neurocrine Biosciences	16.10 Bn	14.78 Bn	800.70 Mn	9.10 Mn
5	Aurora Cannabis	15.56 Bn	15.47 Bn	21.72 Mn	-
6	Elanco Animal Health	12.04 Bn	11.61 Bn	785.00 Mn	51.00 Mn
7	Alkermes	7.36 Bn	6.84 Bn	-116.06 Mn	4.09 Mn
8	Lantheus Holdings	6.74 Bn	6.24 Bn	230.92 Mn	2.04 Mn
9	Liquidia	6.27 Bn	6.04 Bn	121.79 Mn	6.59 Mn
10	Kaya Holdings	-	-	5,370.00	-

Download Data